1.Conditions and Patterns of Intimate Partner Violence among Taiwanese Women.
Fang Hsin LEE ; Yung Mei YANG ; Hsiu Hung WANG ; Joh Jong HUANG ; Shu Chen CHANG
Asian Nursing Research 2015;9(2):91-95
PURPOSE: Intimate partner violence (IPV) is a serious public health issue among women. IPV victims usually seek help from hospitals, and emergency nurses are the frontline staff with whom the victims come into contact first. This study examined the conditions and patterns of IPV in southern Taiwan. METHODS: From designated hospitals in Kaohsiung under the Department of Health Injury Assessment Clinic, data were collected on 497 women regarding their injury assessment for IPV reported to the Kaohsiung City Government. RESULTS: Taiwanese survivors were older compared to immigrant survivors. Taiwanese survivors also had higher education levels compared to immigrant survivors. Taiwanese survivors had higher employment rate than immigrant survivors did. The time between IPV and medical help seeking was longer for divorced than married women. CONCLUSIONS: These results can facilitate understanding of the conditions and patterns of IPV in Taiwan, increase the awareness of nurses, especially the emergency nurses for the prevention of IPV, and increase professional competency for the provision of appropriate healthcare services to survivors of IPV.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Battered Women/*statistics & numerical data
;
Female
;
Humans
;
Intimate Partner Violence/*statistics & numerical data
;
Middle Aged
;
Retrospective Studies
;
Risk Factors
;
Taiwan/epidemiology
;
Young Adult
2.Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.
Chen Wang CHANG ; Shu Chen WEI ; Jen Wei CHOU ; Tzu Chi HSU ; Chiao Hsiung CHUANG ; Ching Pin LIN ; Wen Hung HSU ; Hsu Heng YEN ; Jen Kou LIN ; Yi Jen FANG ; Horng Yuan WANG ; Hung Hsin LIN ; Deng Cheng WU ; Yen Hsuan NI ; Cheng Yi WANG ; Jau Min WONG
Intestinal Research 2014;12(4):287-292
BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria. METHODS: A retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn's Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline. RESULTS: A total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy. CONCLUSIONS: Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.
Adalimumab
;
Crohn Disease*
;
Humans
;
Immunologic Factors
;
Inflammatory Bowel Diseases*
;
Japan
;
Korea
;
National Health Programs
;
Retrospective Studies
;
Taiwan*
3.Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study.
Wei Chen LIN ; Jen Wei CHOU ; Hsu Heng YEN ; Wen Hung HSU ; Hung Hsin LIN ; Jen Kou LIN ; Chiao Hsiung CHUANG ; Tien Yu HUANG ; Horng Yuan WANG ; Shu Chen WEI ; Jau Min WONG
Intestinal Research 2017;15(4):487-494
BACKGROUND/AIMS: In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically focusing on the relapse rate and remission duration; also the response rate to second use when applicable. METHODS: This was a multicenter, retrospective, observational study and we enrolled CD patients who had been treated with adalimumab (ADA) according to the insurance guidelines from 2009 to 2015. RESULTS: A total of 54 CD patients, with follow-up of more than 6 months after the withdrawal of ADA, were enrolled. The average period of treatment with ADA was 16.7±9.7 months. After discontinuing ADA, 59.3% patients suffered a clinical relapse. In the univariate analysis, the reason for withdrawal was a risk factor for relapse (P=0.042). In the multivariate analysis, current smoker became an important risk factor for relapse (OR, 3.9; 95% CI, 1.2−14.8; P=0.044) and male sex was another risk factor (OR, 2.9; 95% CI, 1.1−8.6; P=0.049). For those 48 patients who received a second round of biologics, the clinical response was seen in 60.4%, and 1 anaphylaxis occurred. CONCLUSIONS: Fifty-nine percent of patients experienced a relapse after discontinuing the limited period of ADA treatment, and most of them occurred within 1 year following cessation. Male sex and current smoker were risk factors for relapse. Though 60.4% of the relapse patients responded to ADA again.
Adalimumab*
;
Anaphylaxis
;
Biological Products
;
Budgets
;
Crohn Disease*
;
Follow-Up Studies
;
Humans
;
Inflammatory Bowel Diseases*
;
Insurance
;
Male
;
Multivariate Analysis
;
National Health Programs
;
Observational Study
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Taiwan*
4.Treatment Response Evaluation by Computed Tomography Pulmonary Vasculature Analysis in Patients With Chronic Thromboembolic Pulmonary Hypertension
Yu-Sen HUANG ; Zheng-Wei CHEN ; Wen-Jeng LEE ; Cho-Kai WU ; Ping-Hung KUO ; Hsao-Hsun HSU ; Shu-Yu TANG ; Cheng-Hsuan TSAI ; Mao-Yuan SU ; Chi-Lun KO ; Juey-Jen HWANG ; Yen-Hung LIN ; Yeun-Chung CHANG
Korean Journal of Radiology 2023;24(4):349-361
Objective:
To quantitatively assess the pulmonary vasculature using non-contrast computed tomography (CT) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) pre- and post-treatment and correlate CT-based parameters with right heart catheterization (RHC) hemodynamic and clinical parameters.
Materials and Methods:
A total of 30 patients with CTEPH (mean age, 57.9 years; 53% female) who received multimodal treatment, including riociguat for ≥ 16 weeks with or without balloon pulmonary angioplasty and underwent both noncontrast CT for pulmonary vasculature analysis and RHC pre- and post-treatment were included. The radiographic analysis included subpleural perfusion parameters, including blood volume in small vessels with a cross-sectional area ≤ 5 mm 2 (BV5) and total blood vessel volume (TBV) in the lungs. The RHC parameters included mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), and cardiac index (CI). Clinical parameters included the World Health Organization (WHO) functional class and 6-minute walking distance (6MWD).
Results:
The number, area, and density of the subpleural small vessels increased after treatment by 35.7% (P < 0.001), 13.3% (P = 0.028), and 39.3% (P < 0.001), respectively. The blood volume shifted from larger to smaller vessels, as indicated by an 11.3% increase in the BV5/TBV ratio (P = 0.042). The BV5/TBV ratio was negatively correlated with PVR (r = -0.26; P = 0.035) and positively correlated with CI (r = 0.33; P = 0.009). The percent change across treatment in the BV5/TBV ratio correlated with the percent change in mPAP (r = -0.56; P = 0.001), PVR (r = -0.64; P < 0.001), and CI (r = 0.28; P = 0.049).Furthermore, the BV5/TBV ratio was inversely associated with the WHO functional classes I–IV (P = 0.004) and positively associated with 6MWD (P = 0.013).
Conclusion
Non-contrast CT measures could quantitatively assess changes in the pulmonary vasculature in response to treatment and were correlated with hemodynamic and clinical parameters.
5.Development and characterization of a potential diagnostic monoclonal antibody against capsid protein VP1 of the chicken anemia virus.
Yi Yang LIEN ; Chi Hung HUANG ; Fang Chun SUN ; Shyang Chwen SHEU ; Tsung Chi LU ; Meng Shiunn LEE ; Shu Chin HSUEH ; Hsi Jien CHEN ; Meng Shiou LEE
Journal of Veterinary Science 2012;13(1):73-79
Chicken anemia virus (CAV) is an important viral pathogen that causes anemia and severe immunodeficiency syndrome in chickens worldwide. In this study, a potential diagnostic monoclonal antibody against the CAV VP1 protein was developed which can precisely recognize the CAV antigen for diagnostic and virus recovery purposes. The VP1 gene of CAV encoding the N-terminus-deleted VP1 protein, VP1Nd129, was cloned into an Escherichia (E.) coli expression vector. After isopropyl-beta-D-thiogalactopyronoside induction, VP1Nd129 protein was shown to be successfully expressed in the E. coli. By performing an enzyme-linked immunoabsorbent assay using two coating antigens, purified VP1Nd129 and CAV-infected liver tissue lysate, E3 monoclonal antibody (mAb) was found to have higher reactivity against VP1 protein than the other positive clones according to the result of limiting dilution method from 64 clones. Using immunohistochemistry, the presence of the VP1-specific mAb, E3, was confirmed using CAV-infected liver and thymus tissues as positive-infected samples. Additionally, CAV particle purification was also performed using an immunoaffinity column containing E3 mAb. The monoclonal E3 mAb developed in this study will not only be very useful for detecting CAV infection and performing histopathology studies of infected chickens, but may also be used to purify CAV particles in the future.
Animals
;
Antibodies, Monoclonal/biosynthesis/genetics/*immunology
;
Antigens, Viral/analysis
;
Capsid Proteins/genetics/*immunology
;
Chicken anemia virus/genetics/*immunology
;
*Chickens
;
Circoviridae Infections/blood/immunology/*veterinary/virology
;
Escherichia coli/genetics
;
Immunohistochemistry/veterinary
;
Liver/virology
;
Mice
;
Mice, Inbred BALB C
;
Microscopy, Fluorescence/veterinary
;
Poultry Diseases/blood/immunology/*virology
;
Specific Pathogen-Free Organisms
;
Thymus Gland/virology
6.Biomechanical comparisons between a new avascular necrosis of femaral head stem based on Chinese patients with avascular necrosis and two other designs.
Qiang ZHANG ; Cheng-Kung CHENG ; Hung-Wen WEI ; Xiang DONG ; Yi-Ting CHEN ; Yu-Shu LAI ; Yan WANG
Chinese Medical Journal 2013;126(10):1918-1924
BACKGROUNDThere is a relatively high failure rate of the femoral component in patients with avascular necrosis at the intermediate-term follow-up. Improving the geometrical fit of the femoral stem against the medullary canal may help to provide long-term survivorship of the hip replacement for patients with avascular necrosis.
METHODSWe designed a specific stem, based on morphometric studies of proximal femoral canals in Chinese avascular necrosis patients and evaluated the stem by finite element analyses, comparing the novel stem with two commercially available and commonly used stems.
RESULTSThe morphometric data from avascular necrosis patients showed specific geometric differences in the proximal femoral canal, including profile curves in both the sagittal and coronary planes than the patients with femoral neck fracture. The shorter stemmed prostheses (Fitmore(®) and our stem) performed better than the longer stemmed prosthesis (VerSys(®)).
CONCLUSIONSThis is the first study to investigate the femoral geometries of Chinese avascular necrosis patients. Our stem provides better stability and is theoretically beneficial to bone ingrowth, which may increase the long-term stability and fixation of the implant.
Adult ; Aged ; Biomechanical Phenomena ; Female ; Femur Head Necrosis ; physiopathology ; Finite Element Analysis ; Humans ; Male ; Middle Aged
7.No association between polymorphisms of the DNA repair geneXRCC1 and cervical neoplasm risk.
Ming-Tsang WU ; Shu-Yi CHEN ; Trong-Neng WU ; Hsing-Yu HWANG ; Chi-Kung HO ; Li-Hung LEE ; Su-Chu WU
Environmental Health and Preventive Medicine 2003;8(3):100-103
OBJECTIVESTo investigate the association between genetic polymorphisms ofX-ray repair crosscomplementing group 1 (XRCC1) codons 194, 280, and 399 and cervical neoplasm susceptibility.
METHODSA community-based nested case-control study was conducted. The study population consisted of women living in Chiayi City, located in southwestern Taiwan, who had received pap smear screening between October, 1999, and December, 2000 (n=32,466). The potential cases were women having lesions greater than cervical intraepithelium neoplasm II (C1N2) reconfirmed by cervical biopsy. The potential controls (case: control=1∶2) were age matched (±2 yrs) and residency matched women who had had normal pap smears. In total, 100 cases (39 C1N2, 12 C1N3, 46 carcinoma in situ (CIS), and 3 invasive cancer) and 196 controls had the information on both questionnaire and data ofXRCC1 polymorphisms.
RESULTSThe frequency ofArg/Arg, Arg/Gln, andGln/Gln in codon 399 among cases and controls was 54% (54/100), 38% (38/100), and 8% (8/100) and 58% (114/196), 37% (73/196), and 5% (9/196), respectively, which were not significantly different. No associations were also observed betweenXRCC1 codon 194 and 280 genotypes and cervical neoplasm. While dichotomized by age (<40 vs. ≥40 yrs), smoking status (active and passive smokers vs. non-smokers), and disease status (C1N2 and C1N3 vs. CIS and invasive cancer), the results remained insignificant.
CONCLUSIONSThe present findings suggest thatXRRC1 codon 194, 280 and 399 genotypes may not influence cervical neoplasm risk in the Taiwanese population.
8.Incarcerated Hiatal Hernia with Perforation after Laparoscopic Total Gastrectomy with Roux-en-Y Reconstruction: a Case Report
Nai Yu WANG ; Chung Yu TSAI ; Yuan Yuarn LIU ; I Shu CHEN ; Kai Hung HO
Journal of Gastric Cancer 2019;19(1):132-137
The occurrence of hiatal hernia after total gastrectomy with Roux-en-Y reconstruction is rare. We report the case of a 76-year-old man who presented with dyspnea, vomiting, and fever around 8 days after total gastrectomy with Roux-en-Y reconstruction. Abdominal computed tomography revealed a hiatal hernia containing part of the small intestine in the left thoracic cavity. Emergent reduction and repair of the hiatal hernia were performed later. Operative findings revealed that the Roux limb was incarcerated in the left pleural cavity. Esophagojejunostomy leakage, perforation of the small intestine with transient ischemic change, and pyothorax were also found. Thus, feeding jejunostomy, thoracoscopic decortication, and diversion T-tube esophagostomy were performed. Considering that the main cause of hiatal hernia is blunt dissection with division of the phrenoesophageal membrane, approximating the crus with 1 or 2 figure-8 sutures, according to the size of the defect, to prevent the incidence of hiatal hernia after total gastrectomy may be performed.
Aged
;
Dyspnea
;
Empyema, Pleural
;
Esophagostomy
;
Extremities
;
Fever
;
Gastrectomy
;
Hernia
;
Hernia, Hiatal
;
Humans
;
Incidence
;
Intestine, Small
;
Jejunostomy
;
Membranes
;
Pleural Cavity
;
Stomach Neoplasms
;
Sutures
;
Thoracic Cavity
;
Vomiting
9.Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
Min-Yu LAN ; Hui-Chen L LIN ; Tsung-Hui HU ; Shu-Fang Ch CHEN ; Chien-Hung CHEN ; Yung-Yee CHANG ; King-Wah CHIU ; Tsu-Kung LIN ; Shun-Sheng CHEN
Journal of Clinical Neurology 2023;19(1):52-59
Background:
and Purpose Oral nucleos(t)ide analogs (NAs) are the mainstay treatment for chronic hepatitis B (CHB). Myotoxicity is an important extrahepatic effect related to NA treatment. Telbivudine is the NA for CHB that is frequently associated with muscle-related side effects. The risk factors for telbivudine-induced myopathy (TIM) are not yet clear.
Methods:
This study characterized the clinical, magnetic resonance images (MRI), and pathological features of 12 TIM cases. A group of telbivudine-tolerant (TT) patients with CHB who received regular telbivudine treatment during the same period without the occurrence of myopathy was collected. Demographic and clinical factors were compared between the patients with TIM and the TT controls. Factors independently associated with TIM were identified using logistic regression analysis.
Results:
The patients with TIM (males/females: 7/5, mean age: 57 years) developed myopathy after using telbivudine for a median period of 19.5 months. Muscle histopathology revealed abnormal proliferation, subsarcolemmal or sarcoplasmic accumulations, and ultrastructural defects of mitochondria. When compared with TT cases, patients with TIM had a lower estimated glomerular filtration rate and were more frequently positive for hepatitis B e antigen (HBeAg).
Conclusions
Mitochondrial abnormalities are characteristic histopathological features, and impaired renal function and HBeAg positivity are risk factors for TIM. Telbivudine-induced mitochondrial dysfunction and immune activation related to mitochondrial damage and HBeAg serostatus changes may underlie TIM. Constant clinical surveillance of myopathy during telbivudine treatment is needed due to the significant latency of its development. Dose adjustment for impaired renal function does not eliminate the risk of TIM occurrence.
10.A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease.
Chun Chi LIN ; Shu Chen WEI ; Been Ren LIN ; Wen Sy TSAI ; Jinn Shiun CHEN ; Tzu Chi HSU ; Wei Chen LIN ; Tien Yu HUANG ; Te Hsin CHAO ; Hung Hsin LIN ; Jau Min WONG ; Jen Kou LIN
Intestinal Research 2016;14(3):248-257
BACKGROUND/AIMS: With the recent progress in medical treatment, surgery still plays a necessary and important role in treating ulcerative colitis (UC) patients. In this study, we analyzed the surgical results and outcomes of UC in Taiwan in the recent 20 years, via a multi-center study through the collaboration of Taiwan Society of IBD. METHODS: A retrospective analysis of surgery data of UC patients from January 1, 1995, through December 31, 2014, in 6 Taiwan major medical centers was conducted. The patients' demographic data, indications for surgery, and outcome details were recorded and analyzed. RESULTS: The data of 87 UC patients who received surgical treatment were recorded. The median post-operative follow-up duration was 51.1 months and ranged from 0.4 to 300 months. The mean age at UC diagnosis was 45.3±16.0 years and that at operation was 48.5±15.2 years. The 3 leading indications for surgical intervention were uncontrolled bleeding (16.1%), perforation (13.8%), and intractability (12.6%). In total, 27.6% of surgeries were performed in an emergency setting. Total or subtotal colectomy with rectal preservation (41.4%) was the most common operation. There were 6 mortalities, all due to sepsis. Emergency operation and low pre-operative albumin level were significantly associated with poor survival (P=0.013 and 0.034, respectively). CONCLUSIONS: In the past 20 years, there was no significant change in the indications for surgery in UC patients. Emergency surgeries and low pre-operative albumin level were associated with poor survival. Therefore, an optimal timing of elective surgery for people with poorly controlled UC is paramount.
Colectomy
;
Colitis, Ulcerative*
;
Cooperative Behavior
;
Diagnosis
;
Emergencies
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Inflammatory Bowel Diseases*
;
Mortality
;
Prognosis
;
Retrospective Studies*
;
Sepsis
;
Taiwan*
;
Ulcer*